Global Caspofungin Market
Global Caspofungin Market Projected to Hit USD 590.5 Million by 2034, Asia Pacific Region to Witness Highest Growth Rate
31 janv. 2024 08h19 HE | Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Global Caspofungin Market" report has been added to ResearchAndMarkets.com's offering. New insights into the global caspofungin market have been...
22157.jpg
Insights on the Antifungal Drug Global Market to 2026 - Featuring Abbott Laboratories, Astellas Pharma and Cipla Among Others
04 janv. 2022 05h58 HE | Research and Markets
Dublin, Jan. 04, 2022 (GLOBE NEWSWIRE) -- The "Antifungal Drug Market Research Report by Infection Type, Type, Form, Therapeutic Indications, and Region - Global Forecast to 2026 - Cumulative Impact...
22157.jpg
Global Antifungal Drug Markets Analysis & Forecasts 2021-2026 - Focus on Echinocandins, Azoles, Polyenes, Allylamines
20 août 2021 08h18 HE | Research and Markets
Dublin, Aug. 20, 2021 (GLOBE NEWSWIRE) -- The "Global Antifungal Drug Market (2021-2026) by Drug Type, Indication, Dosage Form, Distribution Channel, Geography, Competitive Analysis and the Impact...
CidaraLogo (1).jpg
Cidara Provides Corporate Update and Reports Second Quarter 2019 Financial Results
08 août 2019 16h07 HE | Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported financial...
CidaraLogo (1).jpg
Cidara Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
07 août 2019 07h30 HE | Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
Positive Topline Results in Phase 2 STRIVE Parts A and B Clinical Trial
Cidara Therapeutics Reports Positive Topline Results in Phase 2 STRIVE B Trial of Antifungal Rezafungin
29 juil. 2019 07h00 HE | Cidara Therapeutics, Inc.
Data from second part of successful Phase 2 STRIVE trial further substantiate the efficacy, safety and tolerability of once-weekly rezafungin for first-line treatment of invasive Candida infections ...